| Li, Lingjiang |
NCT04589143: A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine |
|
|
| Completed | 4 | 137 | RoW | Agomelatine, Placebos | Central South University | Major Depressive Disorder | 12/22 | 01/23 | | |
NCT04160377: A Clinical Trial of Fluvoxamine for Melancholia |
|
|
| Recruiting | 2 | 150 | RoW | Fluvoxamine, Fluvoxamine Maleate Tablets | Lingjiang Li | Depressive Disorder, Endogenous Depression, Melancholia | 06/22 | 09/22 | | |
| Ma, Ning |
NCT06186024: A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL FOR THE NEW SIZES OF BRIDGE STENTS FOR VERTEBRAL ARTERY STENOSIS: Bridge-MAX |
|
|
| Recruiting | N/A | 36 | RoW | Bridge | MicroPort NeuroTech Co., Ltd. | Brain Diseases, Vertebral Artery Thrombosis, Vertebral Artery Stenosis | 07/24 | 01/25 | | |
NCT04627870: ACOART Intracranial ISR Pilot:Intracranial DCB in the Treatment of Intracranial In-stent Restenosis |
|
|
| Recruiting | N/A | 20 | RoW | drug (paclitaxel) coated balloon, PTA balloon | Acotec Scientific Co., Ltd, Beijing Tiantan Hospital | Intracranial Atherosclerosis, Stroke | 12/24 | 12/24 | | |
| Recruiting | N/A | 156 | RoW | Maurora® Sirolimus Eluting Stent System, Maurora, APOLLO™ Intracranial Stent System, APOLLO | Beijing Tiantan Hospital, Alain Medical (Beijing) Co., Ltd. | Intracranial Arteriosclerosis, Stroke (CVA) or TIA | 05/25 | 05/25 | | |
| Not yet recruiting | N/A | 90 | NA | Hyperbaric oxygen therapy, Standard medical treatment, Risk factor management | Beijing Tiantan Hospital | Carotid Stenosis, Cognitive Impairment, Hyperbaric Oxygen Therapy, Stent Implantation | 12/25 | 12/25 | | |
| Yu, Wenjuan |
NCT06082102: Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 324 | RoW | Orelabrutinib, Lenalidomide, Rituximab, Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsed/Refractory Marginal Zone Lymphoma | 08/27 | 02/30 | | |
ICP-CL-01203, NCT06378138: ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Not yet recruiting | 2/3 | 226 | RoW | ICP-248, Orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Hematologic Malignancies | 11/30 | 07/31 | | |
NCT05978739: Evaluating Different Doses of Orelabrutinib in MCL |
|
|
| Recruiting | 2 | 40 | RoW | Orelabrutinib High dose, Orelabrutinib Low dose | InnoCare Pharma Inc., Beijing InnoCare Pharma Tech Co., Ltd. | Mantle Cell Lymphoma | 02/25 | 05/25 | | |
NCT03994913: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma |
|
|
| Completed | 1/2 | 20 | RoW | CAR-CD19 T Cells | CARsgen Therapeutics Co., Ltd., First Affiliated Hospital of Zhejiang University, RenJi Hospital | Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma | 01/21 | 05/21 | | |
NCT05510089: Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies |
|
|
| Recruiting | N/A | 62 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF | The Affiliated People's Hospital of Ningbo University | Hematological Malignancy | 05/24 | 12/24 | | |
2022-YAN-030, NCT05536154: Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies |
|
|
| Recruiting | N/A | 68 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF | The Affiliated People's Hospital of Ningbo University | Lymphoma, Multiple Myeloma | 06/24 | 10/24 | | |
| Zhang, Yan |
NCT05291650: Ultrasound-guided Injection of Glucocorticoid Into Infrapatellar Fat Pad in Patients With Knee Osteoarthritis |
|
|
| Recruiting | 4 | 60 | RoW | Glucocorticoids, Saline, Hyaluronic acid | Zhujiang Hospital | Osteoarthritis, Knee | 07/23 | 12/23 | | |
NCT04790305: Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer |
|
|
| Recruiting | 4 | 1072 | RoW | Huaier Granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast | 12/27 | 07/28 | | |
ETER701, NCT04234607: A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 738 | RoW | TQB2450, Anlotinib, Etoposide, Carboplatin, TQB2450（blank）, Anlotinib（blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Extensive Small Cell Lung Cancer | 12/22 | 12/22 | | |
| Active, not recruiting | 3 | 453 | Europe, US, RoW | MRTX849, adagrasib, KRAZATI, Docetaxel, Taxotere | Mirati Therapeutics Inc. | Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | 12/23 | 12/24 | | |
|
NCT05181137: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
SUNRAY-01, NCT06119581: A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT02159820: Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer |
|
|
| Recruiting | 2/3 | 500 | RoW | Decitabine (DTC Arm), Paclitaxel and Carboplatin (TC Arm) | Chinese PLA General Hospital | Primary Malignant Neoplasm of Ovary, FIGO Stages II to IV | 06/24 | 06/24 | | |
NCT03989336: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
|
|
| Completed | 2 | 84 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Platinum chemotherapy, Sintilimab, anti-PD-1 antibody; PD-1 inhibitor | Chinese PLA General Hospital | Ovarian Cancer | 05/22 | 12/23 | | |
NCT03250962: SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma |
|
|
| Recruiting | 2 | 280 | RoW | SHR-1210, Decitabine | Chinese PLA General Hospital | Hodgkin Lymphoma | 07/22 | 03/25 | | |
LEAD, NCT05092412: Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC |
|
|
| Active, not recruiting | 2 | 30 | RoW | Low-dose radiotherapy, Durvalumab, Etoposide, and cisplatin/carboplatin | You Lu, AstraZeneca | Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab | 02/23 | 06/25 | | |
NCT06176729: Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients |
|
|
| Recruiting | 2 | 30 | RoW | Polatuzumab Vedotin, Rituximab, Lenalidomide | Yan Zhang, MD, Peking University Third Hospital, Peking University First Hospital, Chinese PLA General Hospital | Diffuse Large B Cell Lymphoma | 10/25 | 10/27 | | |
PUMCH-NHL-013, NCT05390749: Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL |
|
|
| Recruiting | 2 | 50 | RoW | Orelabrutinib, Pomalidomide, Rituximab, Methotrexate | Peking Union Medical College Hospital, Beijing Tiantan Hospital, Sanbo Brain Hospital Capital Medical University | Primary Central Nervous System Lymphoma | 04/24 | 04/26 | | |
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA |
|
|
| Recruiting | 2 | 280 | RoW | Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab | Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/28 | | |
IMM01-04, NCT05833984: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas |
|
|
| Recruiting | 1b/2 | 309 | RoW | IMM01, SIRPα Fc, Tislelizumab | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Solid Tumor, Classic Hodgkin Lymphoma | 02/24 | 11/24 | | |
NCT03989310: An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer |
|
|
| Recruiting | 1/2 | 50 | RoW | Manganese Chloride, nab-paclitaxel, Paclitaxel For Injection (Albumin Bound), Gemcitabine, anti-PD-1 antibody, Anti-PD-1 monoclonal antibody; PD-1 inhibitor | Chinese PLA General Hospital | Pancreatic Cancer | 05/21 | 03/22 | | |
NCT04588324: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 50 | RoW | SHR2150, Anti-Cancer Agent | Chinese PLA General Hospital | Solid Tumor | 11/21 | 11/22 | | |
NCT04873440: An Open-label, Phase I/II Study of Manganese Plus Radiotherapy in Patients With Metastatic Solid Tumors or Lymphoma |
|
|
| Recruiting | 1/2 | 10 | RoW | Manganese Chloride, Mn2+, Radiotherapy, Chemo-immunotherapy | Chinese PLA General Hospital | Solid Tumor, Lymphoma | 05/22 | 05/23 | | |
REMLA, NCT04120350: R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty |
|
|
| Recruiting | 1/2 | 47 | RoW | Methotrexate, Rituximab, Lenalidomide | Peking Union Medical College Hospital, Beijing Tiantan Hospital, Xuanwu Hospital, Beijing, Peking University Third Hospital, Beijing Hospital, Peking University First Hospital, Chinese PLA General Hospital | Primary Central Nervous System Lymphoma | 08/22 | 08/24 | | |
NCT05867771: A Study of PM1022 in Patients With Advanced Tumors |
|
|
| Recruiting | 1/2 | 200 | RoW | PM1022 | Biotheus Inc. | Advanced Tumors | 04/24 | 04/25 | | |
NCT05416775: Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 168 | RoW | SHR-8068；Adebrelimab, SHR-8068；adebrelimab and platinum-based chemotherapy, Adebrelimab；platinum-based chemotherapy | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Non-small Cell Lung Cancer | 06/26 | 06/26 | | |
NCT05245916: IBI397 or Combination Therapies in Patients With Advanced Malignancies |
|
|
| Withdrawn | 1a/1b | 30 | RoW | IBI397, IBI397+Sintilimab, IBI397+Rituximab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 08/23 | 08/23 | | |
NCT06271928: A Multicenter Clinical Study of Yijing Keli in the Treatment of Ovarian Aging |
|
|
| Recruiting | 1 | 100 | RoW | Yijing Keli | Tongji Hospital | Ovarian Aging | 01/24 | 01/25 | | |
NCT04487093: Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer |
|
|
| Recruiting | 1 | 20 | RoW | neoantigen vaccine + EGFR-TKI, neoantigen vaccine + anti-angioge | First Hospital of Shijiazhuang City, Tianjin Hengjia Biotechnology Development co., LTD | Non Small Cell Lung Cancer | 05/22 | 12/22 | | |
NCT06256783: A Clinical Study of Baozhu Keli in the Treatment of Ovarian Aging |
|
|
| Recruiting | 1 | 100 | RoW | Baozhu Keli | Tongji Hospital | Ovarian Aging | 01/24 | 01/25 | | |
NCT05114759: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 132 | Japan, RoW | SHR-A2009 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Advanced Solid Tumors | 12/23 | 12/24 | | |
NCT05508334: A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours |
|
|
| Recruiting | 1 | 81 | RoW | RC88, The injectable RC88 | RemeGen Co., Ltd. | Advanced Solid Tumours | 06/24 | 12/24 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
| Recruiting | N/A | 70 | RoW | Plasma exchange, IVIG, High-dose glucocorticoid | Yan Zhang | Autoimmune Encephalitis | 12/21 | 12/23 | | |
NCT03703284: Molecular Mechanisms of Malignant Cerebral Edema After LHI |
|
|
| Recruiting | N/A | 120 | RoW | Treatments to reduce intracranial pressure | Xuanwu Hospital, Beijing | Cerebral Edema | 12/22 | 06/23 | | |
UltraFuture I, NCT05498740: Post-marketing Study in Femoral Popliteal Artery of Drug Coated Balloon Used for Treatment of Lower Limb Ischemia |
|
|
| Recruiting | N/A | 200 | RoW | Drug eluting Balloon | Zhejiang Zylox Medical Device Co., Ltd. | Peripheral Arterial Disease (PAD) | 12/22 | 12/24 | | |
NCT05447572: FIT Combining FC for Predicting MH and Histology Remission in UC |
|
|
| Recruiting | N/A | 300 | RoW | FIT + FC | Shandong University | Ulcerative Colitis, Histology Remission, Fecal Calprotetin, FIT, Mucosal Healing | 12/22 | 12/23 | | |
NCT04361357: The Effects of Enteral Whey Protein Supplement on Serum Albumin Level in Acute Critically Ill Neurological Patients |
|
|
| Recruiting | N/A | 116 | RoW | whey protein | Xuanwu Hospital, Beijing | Nutrition Disorders, Neurologic Disorder | 12/22 | 12/22 | | |
NCT05840861: Using 18F-FPEB PET to Identify mGLUR5 Availability in Affective Disorders |
|
|
| Recruiting | N/A | 59 | RoW | Vortioxetine, Quetiapine | Central South University | Major Depressive Disorder, Bipolar Disorder | 08/23 | 09/23 | | |
DELTA, NCT05608655: DKutting Balloon Versus Chocolate Balloon to Treat Femoral and Popliteal Artery Stenosis |
|
|
| Completed | N/A | 188 | RoW | DKutting LL balloon, Chocolate balloon | DK Medical Technology (Suzhou) Co., Ltd. | Femoral Artery Stenosis, Popliteal Artery Stenosis | 01/24 | 02/24 | | |
NCT06130319: Correlation of Disease Management and Quality of Life in Patients With Chronic Heart Failure and Their Family Caregivers |
|
|
| Recruiting | N/A | 278 | RoW | | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Chronic Heart Failure | 06/24 | 06/24 | | |
| Not yet recruiting | N/A | 768 | RoW | early pancreatic stent placement (EPSP), late pancreatic stent placement (EPSP) | The First Affiliated Hospital of Anhui Medical University, First Affiliated Hospital Bengbu Medical College, Anqing Municipal Hospital, First Affiliated Hospital of Wannan Medical College, Tongcheng People's Hospital of Anhui province, Fuyang people's hospital | Cholangiopancreatography, Endoscopic Rretrograde, Post-ERCP Pancreatitis | 03/26 | 03/26 | | |
NCT06452173: Risk Prediction Model for Cerebrovascular Events in Carotid Artery Stenosis |
|
|
| Enrolling by invitation | N/A | 300 | RoW | Plasma, carotid high-resolution magnetic resonance imaging | Beijing Tiantan Hospital, Beijing Neurosurgical Institute | Carotid Stenosis | 10/26 | 12/26 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
| Wu, Renrong |
NCT05838573: Metformin Treatment on Cognitive Impairment of Schizophrenia |
|
|
| Recruiting | 3 | 120 | RoW | Metformin treatment, Placebo treatment, Baseline assessments, Volunteer assessments | Central South University, NINGBO KANGNING HOSPITAL, Shandong Mental Health Center, The Second People's Hospital of Dali Bai Autonomous Prefecture | Schizophrenia | 07/25 | 12/25 | | |
NCT03932136: Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) |
|
|
| Recruiting | 3 | 300 | RoW | Sulforaphane, ZHIYINGUOSU, Placebo | Shanghai Jiao Tong University School of Medicine, Shanghai Xuhui District Mental Health Center, Shanghai Pudong Nanhui Mental Health Center, Suzhou Psychiatric Hospital, Second Xiangya Hospital of Central South University, Guangzhou Psychiatric Hospital, Shenzhen Fushan Biotech Co., Ltd., Tianjin Anding Hospital, The First Affiliated Hospital of Zhengzhou University, Shenzhen Kangning Hospital | Clinical High Risk Syndrome of Psychosis | 12/25 | 12/26 | | |
NCT04246905: A 12-weeks Study to Evaluate Sulforaphane in the Treatment of Depression |
|
|
| Recruiting | 2 | 90 | RoW | sulforaphane, placedo, selective 5 - HT reuptake inhibitors (SSRI) | Central South University | Depressive Disorder | 12/21 | 12/21 | | |
NCT04521868: A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients |
|
|
| Completed | 2 | 125 | RoW | Sulforaphane, Nutramax, placebo | Central South University | Schizophrenia | 08/22 | 08/22 | | |
NCT05084365: A 6-month Study to Evaluate Sulforaphane Effects in PD Patients |
|
|
| Recruiting | 2 | 100 | RoW | Sulforaphane, Placebo | Central South University | Parkinson Disease | 11/23 | 12/23 | | |
NCT03379597: A 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder |
|
|
| Completed | N/A | 136 | RoW | Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral), Dietary fiber | Central South University | Schizophrenia, Bipolar Disorder | 05/21 | 06/21 | | |
NCT04714970: rTMS on Appetite and Cognitive Function in Schizophrenia |
|
|
| Active, not recruiting | N/A | 10 | RoW | iTBS, Shame stimulation | Central South University, Shanghai Mental Health Center | Schizophrenia | 11/22 | 12/22 | | |
NCT05783063: iTBS for Increased Appetite Induced by Antipsychotics |
|
|
| Recruiting | N/A | 60 | RoW | Active iTBS, Sham iTBS | Central South University | Schizophrenia | 08/24 | 12/24 | | |
NCT03271866: Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome |
|
|
| Recruiting | N/A | 80 | RoW | metformin | Central South University | Schizophrenia | 12/23 | 12/23 | | |
NCT05384405: aiTBS for Relieving NSSI in Depressive Patients |
|
|
| Recruiting | N/A | 60 | RoW | Active iTBS, Sham iTBS | Central South University | Major Depressive Disorder, Bipolar Depression | 02/25 | 02/25 | | |
NCT06428968: Investigating the Insulin Resistance in Individuals With Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 30 | RoW | 160 units nasal insulin spray | Central South University | Type 2 Diabetes | 12/24 | 06/25 | | |
NCT05448430: iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging. |
|
|
| Not yet recruiting | N/A | 50 | RoW | Theta burst stimulation | Central South University | Schizophrenia | 07/24 | 07/24 | | |
NCT05137158: iTBS on Negative Symptoms and Cognitive Function in Schizophrenia |
|
|
| Completed | N/A | 60 | RoW | Intermittent theta burst stimulation, Sham stimulation | Central South University | Schizophrenia | 06/24 | 06/24 | | |
NCT05396989: A Correlation Study of Cognitive Function in Patients With Depression |
|
|
| Not yet recruiting | N/A | 200 | RoW | No intervention | Central South University | Depression | 05/28 | 05/28 | | |
NCT06123897: Establishing a Clinical Database and Biobank for Schizophrenia：A Cohort Study |
|
|
| Recruiting | N/A | 2000 | RoW | Regular follow-up assessments without intervention., Cross-sectional assessment | Central South University | Schizophrenia | 07/28 | 12/28 | | |
